Cyclic Compound inhibitor of 11beta hydroxysteroid dehydrogenase 1； Pharmaceutical Composition and the use thereof in diseases such as diabetes (Div. Sun. 2697 - 11).
BOEHRINGER INGELHEIM INTERNATIONAL GMBH;VITAE PHARMACEUTICAL, INC.
发明人:
RENZ, MARTIN,SCHUELE, MAIN,XU, ZHENRONG
申请号：
CL2014001815
公开号：
CL2014001815A1
申请日:
2014.07.08
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
This invention relates to novel compounds of the Formula Ik, Im1, Im2, Im5, In1, In2, In5, lo1, lo2, lo5, Ip1, Ip3, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.Forma cristalina del (S)-3-((S)-1-(4-(1,6-dihidro-1-metil-6-oxopiridin-3-il)fenil)etil)-6-(2-hidroxi-2-metilpropil-6-fenil-1,3-oxazinan-2-ona monohidrato, modulador de la actividad 11ß-HSD1； composición farmacéutica que lo comprende； útil en el tratamiento de la diabetes mellitus, enfermedades metabólicas, glaucoma, entre otras (divisional de la solicitud CL 2697-11).
